Skadden, Arps, Slate, Meagher & Flom, which has been enjoying an impressive streak of transactions to start 2017, is one of three Am Law 100 firms advising on a proposed $24 billion cash-and-stock deal that will see Becton, Dickinson & Co. acquire medical device manufacturing rival C.R. Bard Inc.
The mega-merger, announced Sunday, will create a powerhouse in the medical supply and technology sector if it closes as expected by the fall of this year. Skadden M&A partners C. Michael Chitwood, Paul Schnell and Thomas Greenberg are leading a team from the firm advising Franklin Lakes, New Jersey-based BD. All three Skadden partners counseled BD in 2014 on its $12.2 billion buy of medical technology company CareFusion Corp.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
